What should one of the country's largest contract research organizations do when it wants to beef up its work in oncology research? Call up Metabolon. American CRO giant Charles River Laboratories ($CRL) is partnering with the North Carolina biomarker developer to further enhance its services in cancer studies, as announced by the CRO on Tuesday at the American Association for Cancer Research annual meeting in Chicago.
The deal is a big win for its clients. By combining Charles River's preclinical oncology study expertise with Metabolon's ability to find mechanisms of action and biomarkers in its analysis of metabolic data, they can provide an array of specialized services. These include, but are not limited to: preclinical expertise in experimental modeling, hundreds of assays and better optimization of experimental and clinical designs.
Metabolon looks to be carrying its strong momentum from 2011 well into 2012, after raising $13.1 million in Series D financing and growing at such a rate that it will need to double its workforce in the near future.
- check out the Charles River release